About this medication
Semaglutide is the active ingredient in several FDA-approved products, including Ozempic, Wegovy, and Rybelsus. The labeled uses differ by product. See our Ozempic and Wegovy pages for brand-specific refill information.
Insurance and coverage
Insurance coverage depends on the specific semaglutide product and its indication. BCBSTX PPO patients can use our insurance pathway before any payment.
Using BCBSTX insurance? Start here
Can this medication be refilled through telehealth?
Semaglutide is the active ingredient used in several FDA-approved products. The exact product, indication, formulation, and current dose matter.
What information may be needed?
- Current product, dose, and dosing schedule
- Date of last dose and any recent interruption
- Current weight and recent weight trend
- Original indication and prior prescriber information
- Recent A1C or glucose data when relevant
- Side effects, other medications, and relevant medical history
- Photo of the current prescription box, pen, bottle, or pharmacy label when available
This is a maintenance-refill pathway, not automatic continuation
To continue therapy, you'll need to show you're already taking this medication, such as a pharmacy label, prior prescription, or records from your prescriber. New starts, restarts after a long gap, or dose increases require a broader evaluation and may not be completed through this refill pathway.
When might GLP-1 continuation not be appropriate through a routine refill visit?
Examples include severe or persistent abdominal pain, repeated vomiting or dehydration, suspected pancreatitis, significant gallbladder symptoms, pregnancy, severe medication reactions, major recent dose changes, or other unstable symptoms. Emergency symptoms require urgent or emergency care.
Insurance and pharmacy availability
The $39 fee is for the clinical evaluation. It does not include medication cost, guarantee insurance authorization, or guarantee that a specific pharmacy has the medication in stock.
Compounded products
Americare evaluates FDA-approved GLP-1 and GIP products only. We do not prescribe compounded semaglutide, compounded tirzepatide, or other compounded GLP-1 products.